- Home
- MLTX vs SGRY Comparison
MLTX vs SGRY Comparison
Compare MLTX & SGRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MLTX | SGRY |
|---|---|---|
| Founded | 2021 | 2004 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hospital/Nursing Management |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MLTX | SGRY |
|---|---|---|
| Price | $11.62 | $14.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $27.50 | $22.25 |
| AVG Volume (30 Days) | 1.6M | ★ 2.5M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.14 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,145,438,000.00 |
| Revenue This Year | N/A | $5.09 |
| Revenue Next Year | N/A | $5.67 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.08 | $11.41 |
| 52 Week High | $23.29 | $23.44 |
Technical Indicators
Market Signals| Indicator | MLTX | SGRY |
|---|---|---|
| Relative Strength Index (RSI) | 29.25 | 51.83 |
| Support Level | $11.06 | $13.26 |
| Resistance Level | $19.24 | $15.02 |
| Average True Range (ATR) | 0.76 | 0.80 |
| MACD | 0.03 | 0.12 |
| Stochastic Oscillator | 7.81 | 53.31 |
Price Performance
Historical ComparisonAbout MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
About SGRY Surgery Partners Inc.
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities, which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earn revenues from contracts with patients in which the performance obligations are to provide health care services.